Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Gut health hope: probiotics may slow kidney disease complication

NCT ID NCT07260682

Disease control Sponsor: Maimónides Biomedical Research Institute of Córdoba Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a daily probiotic drink could slow the buildup of calcium in blood vessels (vascular calcification) in 84 adults with advanced chronic kidney disease. Participants took either the probiotic or a placebo for 6 months, and researchers tracked changes in kidney function, inflammation, and bone mineral levels. The goal was to see if a simple, non-drug supplement could help manage a common complication of kidney disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

84 people

The number who actually took part.

Started

Apr 2021

Finished

Jan 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Be of legal age (≥18 years). 2. Patients with stage 5 CKD in pre-dialysis or dialysis with evidence of cardiovascular disease. Calcification will be quantified using the Kaupilla and Adragao indices as indicated in Appendix 1. All radiographs necessary to assess the degree of calcification (both at the beginning and end of the study) will be examined by the same radiologist. To avoid bias in the assessments, the calculation of the Adragao and Kaupilla indices will be performed by staff from the Radiology Department of the Reina Sofía University Hospital. 3. Negative pregnancy test. 4. Patient capable of understanding the study procedures and who provides informed consent to participate in the research project. Exclusion Criteria: 1 Patients diagnosed with or suspected of having inflammatory bowel disease. 2\. Patients undergoing antibiotic treatment within the last two months prior to the start of the study. 3\. Patients with recurrent infections or diverticula treated intermittently with antibiotics. 4\. No cardiovascular history. 5\. Other cardiovascular or metabolic disorders. 6\. Pregnant or breastfeeding women, or women planning to become pregnant. 7\. Drug or alcohol addiction that, in the investigator's opinion, could interfere with compliance with the study requirements. 8\. Participation in other clinical studies. 9\. Incapacity or unwillingness of the individual, legal guardian, or representative to provide written informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic kidney disease (stages 3B-5) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome end stage renal failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic kidney disease (stages 3B-5)

Contacts and locations

Locations

  • IMIBIC

    Córdoba, Andalusia, 14005, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.